GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
CLINICAL TRIAL DESIGN FOR ORPHAN DRUGS / RARE DISEASES:
Worth a read. AVA6000 can have a more bespoke trial to get it to market.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613711/
Reporting of price sensitive information
AIM Rule 11 requires notification without delay of any new developments which are not public knowledge which, if made public, would cause a significant movement in its share price. The Guidance Notes in part 2 of the AIM Rules make clear that this means information a reasonable investor would be likely to use as part of an investment decision. There is an exemption set out in the guidance relating to transactions which are in the course of negotiation where disclosure might prejudice those negotiations, provided that those who are aware of the information (e.g. the other party to a negotiation and professional advisers) keep that information confidential and do not trade in the company’s shares. The Guidance Notes for Rule 11 also allow companies not to notify information about impending developments in certain circumstances, provided that this information is kept confidential. Companies choosing not to make such information public must have effective procedures and controls in place to ensure confidentiality and minimise the risks of a leak.
Ensure confidentiality??!
A useful retrospective analysis of the use of plain doxorubicin against Soft Tissue Sarcoma. Interesting to see the continued use of doxorubicin suggested as a maintenance therapy. At least there is a robust dataset to compare AVA6000 against.
https://clinicalsarcomaresearch.biomedcentral.com/articles/10.1186/s13569-020-00137-5
The 10 points seemed very reasonable to me.
Answering the point about fortnightly dosing,
Agree limited data released so far. I’d like to see the data for each case. Doxorubicin levels in the tumour cells and its FAP status is essential to know.
Fortnightly dosing: my take is the evidence so far suggests this is safe and will improve efficacy. AVA6000 should allow a higher peak and sustained higher intratumour levels of free doxorubicin. Growing evidence it’s not just DNA replication damage that causes tumour cell death. Fingers crossed we see enhanced killing with higher drug levels.
Not sure if a higher dose - peak and total delivered to the tumour - might help reduce Multi Drug Resistance.
1) Thrush : a bird.
2) Thrush: a fungal infection of, in particular, female genitalia. Causing inflammation and severe irritation.
3) Thush: a highly annoying person, ‘an irritating c@@t’.
Certainly here in force today.
Good point PL75. I’ll take the AVA6000 please, upping the dose of plain dox is going to fry peoples nerves.
https://link.springer.com/article/10.1007/s12640-023-00652-5
Please don’t take this as FUD. Something to be aware of. A small molecule drug is undergoing clinical trials to see if it reduces / stops the cardiotoxicity of doxorubicin. No mention of it reducing the bone marrow suppression effects of doxorubicin. Important we know about this. Though it will potentially allow higher doses of doxorubicin, they won’t be targeted directly into the TME. And AVA6000 is just one of many prodrugs that will be developed off the platform.
https://www.cancer.gov/news-events/cancer-currents-blog/2020/doxorubicin-target-bax-prevent-heart-damage
Time to fight back:
https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcTCYmxvuUyj-xBPXh1rSz3ndot82nbBPqOVDA&usqp=CAU
Ice, a serious and definitely not FUD answer. We know Avacta are having serious conversations with interested parties. Licensing, JV, and TO are all possibilities. If they’ve also negotiated a placing BUT at a good price per share, not a bucket shop offer, then it gives them financial resilience going forward. It de risks the business, and allows negotiation from a better position. We know Pharma research is expensive, having this buffer in place makes sense. We also know how much further along the AVA platform is since the CLN. Far far more worth in the IP now. Just a thought.
GLA, hope we’re all heading back the way we should be. 🤞🏻✊🏻
Wyn, I hope this isn’t a ‘dead cat bounce’ today. As was posted earlier, £1.00 seems to be the point around which the price oscillates at present. Possibly an overshoot and settle back to that in the coming week or so.